Business News • PR NewsWire • ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema

ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema

ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema

LEUVEN, Belgium, April 20, 2017 /PRNewswire/ -- ThromboGenics, a biotechnology company focusing on novel treatments for back of the eye disease and diabetic eye disease, announced it has achieved an important milestone in the advancing of the pre-clinical development of its THR-149, a...

View More : http://www.prnewswire.com/news-releases/thrombogenics-achieves-important-milestone-in-the-development-of-thr-149-a-novel...

Releted News by prnewswire

Patrimoine & Commerce: activité du 1er trimestre 2017 - loyers bruts en progression de +4,5 % à 10,3 M€

Forte croissance de Virgin Mobile Moyen-Orient et Afrique qui dessert plus de 3,5 millions de clients via la plate-forme Symsoft pour opérateurs de réseau mobile virtuel